Bivalent Vaccine Effectiveness Among Adults Aged ≥65 Years During the BA.5-Predominant Period in Japan: The VENUS Study.
Wataru MimuraChieko IshiguroJunko Terada-HirashimaNobuaki MatsunagaMegumi MaedaFumiko MurataHaruhisa FukudaPublished in: Open forum infectious diseases (2023)
The study showed that the bivalent mRNA vaccines as the second and third doses would provide protection against COVID-19 among adults ≥65 years in Japan.